Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.34 |
| ▸ | DYRK2 | Q92630 | 8/20 | 0.34 |
| ▸ | CDK9 | P50750 | 4/20 | 0.34 |
| ▸ | CLK1 | P49759 | 2/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | CLK3 | P49761 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30349256 | 1.00 | DYRK1A (0.34) | DYRK1ADYRK2CDK9CLK1CSNK1E | |
| SCHEMBL25215258 | 1.00 | DYRK1A (0.34) | DYRK1ADYRK2CDK9CLK1CSNK1E | |
| SCHEMBL25220480 | 0.94 | DYRK1A (0.41) | DYRK1ADYRK2CDK9CLK1CSNK1E | |
| SCHEMBL30347060 | 0.94 | DYRK1A (0.41) | DYRK1ADYRK2CDK9CLK1CSNK1E | |
| SCHEMBL25220479 | 0.94 | DYRK1A (0.41) | DYRK1ADYRK2CDK9CLK1CSNK1E | |
| SCHEMBL30347188 | 0.80 | DYRK1A (0.42) | DYRK1ADYRK2CDK9CLK1CSNK1E | |
| SCHEMBL25157848 | 0.80 | DYRK1A (0.42) | DYRK1ADYRK2CDK9CLK1CSNK1E | |
| SCHEMBL25265573 | 0.80 | DYRK1A (0.42) | DYRK1ADYRK2CDK9CLK1CSNK1E | |
| SCHEMBL25523144 | 0.78 | MAPK14 (0.33) | DYRK1ADYRK2CDK9CLK1CLK2 | |
| SCHEMBL30349201 | 0.73 | CDK9 (0.36) | DYRK1ADYRK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | DYRK1A 1/4885DYRK2 3/4885CDK9 94/4885 |
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | DYRK1A 1/4885DYRK2 3/4885CDK9 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.